Leaflet ELIGARD 22.5mg lyophilisate and solvent for solution for injection
- Product code:
- W43179001
- Quantity:
- 1
- Indicated for:
- prostate cancer; breast cancer; endometriosis
- Route of administration:
- injectable
- Substance:
- leuprorelin (GnRH agonist)
- ATC
- L02AE02 — Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.
Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.
Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.
General data about ELIGARD 22.5mg
- Substance:
- leuprorelin
- Date of latest medicines list:
- 01-01-2014
- Product code:
- W43179001
- Concentration:
- 22.5mg
- Pharmaceutical form:
- lyophilisate and solvent for solution for injection
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Pharmaceutical forms available for leuprorelin
Concentrations available for leuprorelin
- 11.25mg
- 22.5mg
- 3.75mg
- 42mg
- 45mg
- 5mg
- 7.5mg